|
|
Volumn 16, Issue 1, 2016, Pages
|
|
Survival, safety, and prognostic factors for outcome with Regorafenib in patients with metastatic colorectal cancer refractory to standard therapies: Results from a multicenter study (REBACCA) nested within a compassionate use program
a
|
|
Author keywords
Antiangiogenic; Cohort study; Colorectal cancer; Metastatic disease; Regorafenib
|
|
Indexed keywords
REGORAFENIB;
ANTINEOPLASTIC AGENT;
CARBANILAMIDE DERIVATIVE;
KRAS PROTEIN, HUMAN;
PROTEIN P21;
PYRIDINE DERIVATIVE;
ADULT;
AGED;
ANOREXIA;
ARTICLE;
CANCER PROGNOSIS;
CANCER SURVIVAL;
COHORT ANALYSIS;
COMPASSIONATE USE;
DESQUAMATION;
DIARRHEA;
DRUG DOSE REDUCTION;
DRUG FATALITY;
DRUG SAFETY;
FATIGUE;
FOLLOW UP;
FUNCTIONAL STATUS;
GENE MUTATION;
HAND FOOT SYNDROME;
HUMAN;
HYPERBILIRUBINEMIA;
HYPERTENSION;
LIVER METASTASIS;
MAJOR CLINICAL STUDY;
METASTATIC COLORECTAL CANCER;
MORTALITY;
MUCOSA INFLAMMATION;
MULTICENTER STUDY (TOPIC);
MYALGIA;
ONCOGENE K RAS;
PROTEINURIA;
RANDOMIZED CONTROLLED TRIAL (TOPIC);
RASH;
SIDE EFFECT;
SURVIVAL RATE;
THROMBOCYTOPENIA;
TREATMENT OUTCOME;
VERY ELDERLY;
CLINICAL TRIAL;
COLORECTAL NEOPLASMS;
CONTROLLED STUDY;
FEMALE;
GENETICS;
KAPLAN MEIER METHOD;
MALE;
METASTASIS;
MIDDLE AGED;
MULTICENTER STUDY;
MUTATION;
PHASE 3 CLINICAL TRIAL;
PROGNOSIS;
RANDOMIZED CONTROLLED TRIAL;
SURVIVAL ANALYSIS;
ADULT;
AGED;
AGED, 80 AND OVER;
ANTINEOPLASTIC AGENTS;
COHORT STUDIES;
COLORECTAL NEOPLASMS;
COMPASSIONATE USE TRIALS;
FEMALE;
HUMANS;
KAPLAN-MEIER ESTIMATE;
MALE;
MIDDLE AGED;
MUTATION;
NEOPLASM METASTASIS;
PHENYLUREA COMPOUNDS;
PROGNOSIS;
PROTO-ONCOGENE PROTEINS P21(RAS);
PYRIDINES;
SURVIVAL ANALYSIS;
TREATMENT OUTCOME;
|
|
EID: 84977485913
PISSN: None
EISSN: 14712407
Source Type: Journal
DOI: 10.1186/s12885-016-2440-9 Document Type: Article |
|
Times cited : (109)
|
|
References (6)
|
